



# Algorithm for WHO Recommended Diagnostics (WRDs) (MGIT Culture)

Module 1: WHO recommended TB diagnostic assays & algorithms

Date:

By:

Uganda Supranational Reference Laboratory



## Content Outline



- Materials for MGIT Culture
- WHO endorsed TB diagnostic techniques until 2017



## Materials



## **BD MGIT**

## techniques for diagnosing TB: until 2017

MUO 2 LECOIIIIIEIIGEA



IMPLEMENTING TUBERCULOSIS **DIAGNOSTICS** 

#### **Microscopy**

- Conventional light microscopy
- Light-emitting diode fluorescent microscopy

#### **Culture**


- Culture on solid media
- Commercial liquid culture systems and rapid speciation

### **Drug-susceptibility testing**

- DST first-line anti-TB agents
- DST for second-line anti-TB agents
- Non-commercial methods

### Molecular testing

- LPA (first and second-line)
- TB-LAMP
- Xpert MTB/RIF assay (Ultra+others)
- LF-LAM Urine test for PLHIV




Available at: http://www.who.int/tb/dots/laboratory/policy/en






# tests at the levels of laboratory sophistication





Flow Chart 1: General Algorithm MGIT 960 Cultures






(and revised TTD

applicable).


from Appendix M, if



Flow Chart 2: Contaminated MGIT Cultures







#### Suspected MOTT (from Flow Chart 1)

ZN – Positive BAP – Negative

Rapid ID test – Negative or invalid **Action:** Reincubate for 48 hours and retest with Rapid ID test.

If MTB – positive from rapid ID test Report: ZN positive, BAP negative, Positive for MTB, original TTD from MGIT printout.

If MTB – negative or invalid from rapid ID test

Action: Perform HAIN GenoType® Mycobacterium CM or HAIN GenoType® MTBDRplus.

- If MTB positive on GenoType®
   Mycobacterium CM or GenoType®
   MTBDRplus test
   Report: ZN positive, BAP negative,
   Positive for MTB, original TTD from
   MGIT printout.
- → If positive for MOTT on GenoType® Mycobacterium CM test, or MTB negative on GenoType® MTBDRplus Report: ZN positive, BAP negative, No TB growth, but positive for other mycobacteria, original TTD from MGIT printout.

If test remains invalid: decontaminate MGIT, repeat rapid ID test and notify Sponsor representative.

#### Suspected MOTT (from Flow Chart 2)

ZN – Positive BAP – Growth

Rapid ID test – Negative or invalid **Action:** Reincubate for 48 hours and retest with Rapid ID test.

If MTB – positive from rapid ID test

Report: ZN positive, BAP contaminated,
Positive for MTB and Contaminated,
original TTD from MGIT printout
(and final TTD from Appendix M, if
applicable).

If MTB – negative or invalid from rapid ID test


Action: Perform HAIN GenoType® Mycobacterium CM or HAIN GenoType® MTBDRplus.

- → If MTB positive on GenoType® Mycobacterium CM or GenoType® MTBDRplus test Report: ZN positive, BAP contaminated, Positive for MTB and contaminated, original TTD from MGIT printout (and final TTD from Appendix M, if applicable).
- → If positive for MOTT on GenoType® Mycobacterium CM test, or MTB negative on GenoType® MTBDRplus Report: ZN positive, BAP contaminated, No TB growth, but positive for other mycobacteria, original TTD from MGIT printout (and final TTD from Appendix M, if applicable).

If test remains invalid: decontaminate MGIT repeat rapid ID test and notify Sponsor representative.




Flow Chart 3: MGIT "Early Positive" Cultures (ZN/BAP negative)







Flow Chart 3: MGIT "Early Positive" Cultures (ZN/BAP negative)







# Group exercise-10 minutes

1. List all the WHO approved TB diagnostic tests that you know

2. Identify the role of each of those tests in the MTB MGIT culture diagnostic algorithm.





## Assessment

1. What is the role of culture & phenotypic DST in the diagnosis & management of TB with the advent of the rapid and more sensitive TB diagnostic assays?



## Summary



- Laboratories play a significant role under the End TB Strategy
- 2. Increasing access to rapid detection of TB and reaching universal access to DST will require major efforts
- 3. Future diagnostics will play a role in reaching targets of End TB Strategy, but we also need to make the best use of the currently available diagnostics
- 4. Multi-disease testing platforms will provide opportunities for laboratory integration
- 5. Connectivity provides opportunities for improved quality assurance and patient care
- 6. Adoption of WHO policy guidance on new TB diagnostics combined with use of GLI implementation guidance can help countries reachethering



## References



www.gliafricatb.org

www.who.int/tb

 http://www.who.int/tb/publications/molecu lar-test-resistance/en

http://www.who.int/tb/dots/laboratory/pol

MG/PP/001, Version 1.0, Effective date: 01-Jun-2019



## Acknowledgments

01-Jun-2019















Timely Accurate Diagnostics for a 18-free Africa G'PP/001, Version 1.0, Effective date: